Drug Ther Bull. 2015 Mar;53(3):30-2. doi: 10.1136/dtb.2015.3.0313.
Lurasidone (Latuda-Sunovion) is a new oral second-generation antipsychotic licensed for treating adults with schizophrenia. Although less likely to cause extrapyramidal adverse effects than first-generation antipsychotics, some second-generation antipsychotics cause weight gain that may increase the risk of diabetes, hypertension and raised lipid levels.1,2 Lurasidone is promoted as offering a balance between efficacy and tolerability, with reported negligible effects on weight and minimal effects on glucose and cholesterol.3 Here we review evidence for lurasidone's efficacy and safety, and consider how it compares with other antipsychotics.
鲁拉西酮（Latuda - Sunovion）是一种新型口服第二代抗精神病药物，已获许可用于治疗成人精神分裂症。尽管第二代抗精神病药物比第一代抗精神病药物引起锥体外系不良反应的可能性较小，但一些第二代抗精神病药物会导致体重增加，这可能会增加患糖尿病、高血压和血脂升高的风险。1,2鲁拉西酮被宣传为在疗效和耐受性之间取得了平衡，据报道其对体重的影响可忽略不计，对血糖和胆固醇的影响也最小。3在此，我们回顾鲁拉西酮疗效和安全性的证据，并探讨它与其他抗精神病药物相比如何。
